Should You Microdose GLP-1 Drugs for Weight Loss (Economist)

Section: Science & technology (Well Informed column) · Edition: 2026-07-25 Edition · Print headline: "Does microdosing GLP-1 drugs work?"

Summary

A Well Informed column on the spread of GLP-1 Microdosing: taking less than the label dose of a GLP-1 receptor agonist (semaglutide, tirzepatide) as a goal in itself, rather than as a step on the way up to or down from a full dose. The Economist frames it as "one of the biggest off-label medical experiments ever": widespread, commercially organised in America, and running almost entirely without trial evidence. No specific study is reported; the piece is reportage on practice, guidance and the gap between them.

Key claims

• Prevalence. One estimate puts the share of GLP-1 users who have microdosed at about one in seven.
• Unsupervised use. One small survey found as many as 55% of microdosers do it without medical supervision ("lone rangers").
• An industry has formed. In America microdosing is offered by large online firms (Noom, Hims & Hers) and by many medical spas; a lot of people also self-administer at home.
• Routine vs goal. Dose titration (starting low to manage side-effects; stepping down rather than stopping "cold turkey") is normal clinical practice. The contested case is microdosing as the goal: to cut cost or out of fear of side-effects.
• Guidance. The American Association of Clinical Endocrinology says the evidence is largely anecdotal and advises doctors to stick to FDA-approved dosing. A paper published in April 2026 suggests responses to the drugs vary with an individual's genes, which is the only research signal the article cites in microdosing's favour.
• Clinician counter-view. Some clinicians report "super responders" who do well on lower doses, and patients who, having reached a weight-loss goal, hold it on a smaller long-term maintenance dose, under supervision.
• Mechanics of DIY dosing. Pens deliver fixed doses as "clicks". Microdosers either draw drug out with a syringe (contamination risk) or count clicks to under-dose (error-prone); both can push a pen past its 30–60 day shelf life.
• The benefits beyond weight may not come. The trials showing cardiovascular and other benefits used full doses; there is no evidence yet that lower doses deliver them.
• No one is likely to run the trial. Pharma firms have little motive to fund research that might show less of their product works.

What is flagged as unproven

• Whether microdosing produces or maintains weight loss at all (evidence: anecdote plus one gene-response paper).
• Whether any non-weight benefit (cardiovascular, kidney, sleep apnoea, as catalogued on GLP-1s) survives at sub-label doses.
• The actual size of the practice: the "one in seven" and "55% unsupervised" figures come from one estimate and one small survey, neither named.

Connects to

• GLP-1 Microdosing — concept page for this practice
• GLP-1s — the drug class; this is the consumer-behaviour underside of the platform story
• Eli Lilly — the manufacturer whose pens are being click-counted; the LillyDirect direct-to-consumer channel is where price pressure meets this behaviour
• Type 2 Diabetes Remission — the drug-free route to metabolic remission that sits alongside pharmacological weight loss
• Eli Lilly Is Reinventing the Pharma Business (Economist) — the same vault thread from the supply side